131 results
Page 6 of 7
6-K
EX-99.1
ndxq9rs6lnqhp0yqys
19 Mar 20
Current report (foreign)
7:25am
6-K
ackormovtdq qdpc1
14 Nov 19
Current report (foreign)
7:01am
6-K
EX-99.2
vm43ynvmu51u
1 Nov 19
Current report (foreign)
4:15pm
6-K/A
x44c59f
29 Aug 19
Current report (foreign) (amended)
5:25pm
6-K
vo693
13 Aug 19
Current report (foreign)
7:00am
6-K
EX-10.1
zt2plo9 xij7vr
17 May 19
Current report (foreign)
5:20pm
424B5
626k5xf5
17 May 19
Prospectus supplement for primary offering
5:19pm
6-K
7kail
15 May 19
Current report (foreign)
7:00am
6-K
e64w3bd4rs0
20 Nov 18
Current report (foreign)
7:00am
6-K
EX-99.1
tgg4ervqqt1gjw
16 Nov 18
Current report (foreign)
8:46am
6-K
EX-99.1
905wz9
23 Oct 18
Newly Granted European Composition of Matter Patent Extends Exclusive Protection for VBL Therapeutics’ Lead Drug Candidate VB-111 until October 2033
8:16am
6-K
EX-99.2
32jvhtdr2pz
15 Oct 18
Notice of Annual General Meeting of Shareholders
8:15am
6-K
90o8hxgw f1r5
16 Aug 18
Current report (foreign)
7:00am
424B5
3ccl0p
27 Jun 18
Prospectus supplement for primary offering
9:30am
6-K
EX-1.1
7vq 7xcklblkl7
27 Jun 18
VBL Therapeutics Announces $15.5 Million Registered Direct Offering Priced At-the-Market
9:29am
6-K
mq45kkc71lvtb8zl34p
17 May 18
Current report (foreign)
7:00am